Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 53,375 $ 84,043
Marketable securities - available-for-sale debt securities 108,459 124,218
Accounts receivable, net of allowance for doubtful accounts of $0 and $0 5,052 206
Other current assets and prepaid expenses (including current portion of clinical materials) 28,777 21,716
Total current assets 195,663 230,183
Restricted cash 4,360 4,253
Clinical materials 4,572 4,695
Property, plant and equipment, net 41,235 40,679
Intangibles, net 1,238 1,337
Total assets 247,068 281,147
Current liabilities    
Accounts payable 5,051 8,378
Accrued expenses and other accrued liabilities 19,650 27,201
Deferred revenue 27,221 38,735
Total current liabilities 51,922 74,314
Other liabilities, non-current 3,884 3,849
Total liabilities 55,806 78,163
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 701,103,126 authorized and 564,859,960 issued and outstanding (2017: 701,103,126 authorized and 562,119,334 issued and outstanding) 858 854
Additional paid in capital 461,603 455,401
Accumulated other comprehensive loss (27,136) (21,641)
Accumulated deficit (244,063) (231,630)
Total stockholders' equity 191,262 202,984
Total liabilities and stockholders' equity $ 247,068 $ 281,147